Total Payments
$920,269
2024 Payments
$160,086
Companies
44
Transactions
1,948
Medicare Patients
1,723
Medicare Billing
$1.7M
Payment Breakdown by Category
Other$375,531 (40.8%)
Research$248,696 (27.0%)
Consulting$205,502 (22.3%)
Travel$52,846 (5.7%)
Food & Beverage$37,534 (4.1%)
Education$159.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $363,146 | 187 | 39.5% |
| Unspecified | $248,696 | 184 | 27.0% |
| Consulting Fee | $205,502 | 94 | 22.3% |
| Travel and Lodging | $52,846 | 203 | 5.7% |
| Food and Beverage | $37,534 | 1,269 | 4.1% |
| Honoraria | $12,385 | 8 | 1.3% |
| Education | $159.50 | 3 | 0.0% |
Payments by Type
General
$671,573
1,764 transactions
Research
$248,696
184 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $199,779 | 478 | $0 (2024) |
| Glenmark Pharmaceuticals Inc. | $136,021 | 98 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $72,845 | 180 | $0 (2024) |
| ABBVIE INC. | $68,168 | 84 | $0 (2024) |
| GENZYME CORPORATION | $57,011 | 105 | $0 (2024) |
| Genentech USA, Inc. | $53,828 | 167 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $38,962 | 63 | $0 (2024) |
| Ichnos Sciences Inc. | $37,446 | 6 | $0 (2020) |
| PFIZER INC. | $31,982 | 80 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $27,465 | 57 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $160,086 | 316 | AstraZeneca Pharmaceuticals LP ($50,869) |
| 2023 | $96,963 | 264 | AstraZeneca Pharmaceuticals LP ($31,996) |
| 2022 | $108,050 | 226 | ABBVIE INC. ($20,804) |
| 2021 | $112,510 | 200 | AstraZeneca Pharmaceuticals LP ($36,584) |
| 2020 | $102,206 | 191 | Ichnos Sciences Inc. ($37,446) |
| 2019 | $195,976 | 322 | Glenmark Pharmaceuticals Inc. ($126,418) |
| 2018 | $92,609 | 269 | AstraZeneca Pharmaceuticals LP ($31,521) |
| 2017 | $51,869 | 160 | Circassia Pharmaceuticals Inc ($26,387) |
All Payment Transactions
1,948 individual payment records from CMS Open Payments — Page 1 of 78
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $3.86 | General |
| Category: Inflammation | ||||||
| 12/19/2024 | Genentech USA, Inc. | Xolair (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Genentech USA, Inc. | Xolair (Biological) | Travel and Lodging | In-kind items and services | $1,452.00 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: Immunology | ||||||
| 12/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,132.00 | General |
| Category: Immunology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 12/12/2024 | Octapharma USA, Inc. | CUTAQUIG (Biological) | Food and Beverage | In-kind items and services | $24.84 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | Cash or cash equivalent | $14.78 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | Cash or cash equivalent | $7.02 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | Cash or cash equivalent | $3.11 | General |
| Category: Immunology | ||||||
| 12/11/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $39.96 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 12/10/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Inflammation | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: Respiratory | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 12/09/2024 | Amgen Inc. | — | Food and Beverage | Cash or cash equivalent | $95.98 | General |
| 12/09/2024 | Amgen Inc. | — | Travel and Lodging | Cash or cash equivalent | $15.00 | General |
| 12/09/2024 | Genentech USA, Inc. | Xolair (Biological) | Travel and Lodging | In-kind items and services | $15.00 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Food and Beverage | In-kind items and services | $56.91 | General |
| Category: GENETIC DISEASE | ||||||
| 12/03/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: Immunology | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $25.25 | General |
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $22.42 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $21.65 | General |
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | Cash or cash equivalent | $55.73 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD) | Glenmark Pharmaceuticals Inc. | $126,418 | 59 |
| GBR830-204 | Ichnos Sciences Inc. | $37,446 | 6 |
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $17,655 | 5 |
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $13,740 | 10 |
| A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study Investigating the Efficacy Safety Pharmacokinetics and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate to Severe Atopic Dermatitis AD | Glenmark Pharmaceuticals Inc. | $9,604 | 39 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $9,314 | 2 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $6,622 | 8 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients 12 to 18 Years of Age, With Moderate-to-severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $4,457 | 11 |
| A PHASE IV PROSPECTIVE STUDY TO EVALUATE PREDICTORS OF CLINICAL RESPONSE TO OMALIZUMAB | F. Hoffmann-La Roche AG | $3,150 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL- GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS | Regeneron Pharmaceuticals, Inc. | $2,658 | 4 |
| AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $2,573 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PATIENTS >=12 TO <18 YEARS OF AGE, WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $2,244 | 2 |
| AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS | Regeneron Pharmaceuticals, Inc. | $2,241 | 8 |
| Registry of Asthma Patients Initiating DUPIXENT (RAPID) | GENZYME CORPORATION | $1,500 | 4 |
| The CHRONICLE Study is a multi center non interventional prospective cohort study of adults with severe asthma who do not achieve control with high dose inhaled corticosteroid ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibody therapy | AstraZeneca Pharmaceuticals LP | $1,395 | 1 |
| A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 Peanut Oral Immunotherapy | Regeneron Pharmaceuticals, Inc. | $1,305 | 6 |
| An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials | Regeneron Pharmaceuticals, Inc. | $1,293 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $1,128 | 2 |
| A Phase IV Prospective Study To Evaluate Predictors of Clinical Response To Omalizumab | F. Hoffmann-La Roche AG | $980.00 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $950.08 | 2 |
| An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials | SANOFI-AVENTIS U.S. LLC | $717.04 | 2 |
| A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $599.27 | 2 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO ASSESS THE EFFICACY SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $419.80 | 1 |
| OLE | SANOFI-AVENTIS U.S. LLC | $177.85 | 1 |
| An Open-Label, Drug-Drug Interaction Study to Examine the Effects of Dupilumab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Patients With Moderate to Severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $70.94 | 2 |
| A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $37.71 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 450 | 19,279 | $1.2M | $606,915 |
| 2022 | 13 | 397 | 16,027 | $822,272 | $526,596 |
| 2021 | 13 | 358 | 11,095 | $408,993 | $248,241 |
| 2020 | 15 | 518 | 14,802 | $525,979 | $316,813 |
Total Patients
1,723
Total Services
61,203
Medicare Billing
$1.7M
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 32 | 14,400 | $820,423 | $434,084 | 52.9% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2023 | 11 | 1,020 | $240,960 | $134,719 | 55.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 76 | 123 | $16,113 | $10,501 | 65.2% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 48 | 796 | $12,736 | $7,854 | 61.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 47 | 561 | $14,586 | $5,504 | 37.7% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 56 | 584 | $26,229 | $4,039 | 15.4% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 27 | 1,325 | $10,600 | $3,654 | 34.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 35 | 35 | $6,774 | $3,477 | 51.3% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2023 | 18 | 257 | $4,112 | $1,439 | 35.0% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 30 | 38 | $3,192 | $689.40 | 21.6% |
| 95115 | Professional service for single injection of allergen | Office | 2023 | 14 | 71 | $1,491 | $452.40 | 30.3% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2023 | 32 | 36 | $972.00 | $443.02 | 45.6% |
| 96160 | Administration and interpretation of patient-focused health risk assessment | Office | 2023 | 24 | 33 | $495.00 | $59.54 | 12.0% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2022 | 24 | 10,605 | $456,015 | $316,736 | 69.5% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2022 | 13 | 1,320 | $261,360 | $174,862 | 66.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 48 | 69 | $9,039 | $6,352 | 70.3% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 37 | 1,885 | $15,080 | $5,485 | 36.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 41 | 41 | $7,802 | $5,013 | 64.3% |
| 95117 | Professional service for multiple injections of allergen | Office | 2022 | 47 | 628 | $41,454 | $4,750 | 11.5% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 39 | 423 | $6,768 | $4,554 | 67.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 38 | 438 | $11,388 | $4,420 | 38.8% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2022 | 31 | 523 | $8,368 | $3,187 | 38.1% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 25 | 29 | $2,436 | $570.93 | 23.4% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 12 | 12 | $1,524 | $341.09 | 22.4% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2022 | 17 | 19 | $513.00 | $256.92 | 50.1% |
About Dr. Weily Soong, M.D
Dr. Weily Soong, M.D is a Specialist healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316981608.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Weily Soong, M.D has received a total of $920,269 in payments from pharmaceutical and medical device companies, with $160,086 received in 2024. These payments were reported across 1,948 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($363,146).
As a Medicare-enrolled provider, Soong has provided services to 1,723 Medicare beneficiaries, totaling 61,203 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Birmingham, AL
- Active Since 06/16/2006
- Last Updated 05/15/2012
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1316981608
Products in Payments
- DUPIXENT (Biological) $101,682
- Xolair (Biological) $63,882
- AIRSUPRA (Drug) $58,818
- RINVOQ (Biological) $51,955
- FASENRA (Drug) $47,779
- GBR830-204 (Drug) $37,446
- DUPIXENT DUPILUMAB INJECTION (Biological) $30,194
- DUPIXENT (Drug) $24,216
- FASENRA (Biological) $23,541
- TEZSPIRE (Biological) $20,436
- TAPINAROF (Drug) $19,744
- NUCALA (Biological) $16,372
- CIBINQO (Drug) $11,508
- Xhance (Drug) $11,410
- NIOX VERO DEVICE (Device) $8,732
- ADBRY (Biological) $8,400
- Xembify (Biological) $6,220
- CINQAIR (Biological) $6,186
- OPZELURA (Drug) $5,979
- CINQAIR (Drug) $4,807
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Birmingham
Mrs. Emily Riser, Md, MD
Specialist — Payments: $372,369
Specialist $372,369
Dr. Pamela Mclain, M.d, M.D
Specialist — Payments: $340,290
Specialist $340,290
Dr. Michael Sillers, Md, MD
Specialist — Payments: $286,019
Specialist $286,019
Jason Thompson, M.d, M.D
Specialist — Payments: $228,177
Specialist $228,177
Dr. Stanley Hewlett, Md, MD
Specialist — Payments: $116,582
Specialist $116,582
Dr. John Riser, Md, MD
Specialist — Payments: $41,767
Specialist $41,767